Randomized trial shows MRD dynamics predict survival in newly-diagnosed multiple myeloma, suggesting implications for treatment.
Key Points
The research aims to explore how multiple measurable residual disease (MRD) assessments can predict outcomes and determine the timing of immunotherapy in multiple myeloma patients.
Computed MRD dynamics using next-generation flow cytometry in 539 newly-diagnosed MM patients with ≥3 assessments.
Executed molecular and immune profiling on matched diagnostic and MRD samples.
Investigated survival impact of treating persistent MRD vs relapse with anti-BCMA CAR T cells in mouse models.
Identified five MRD dynamics subgroups correlating with survival outcomes.
Patients with late-sustained MRD response had similar excellent outcomes to those with early-sustained MRD response.
MRD dynamics predicted progression more effectively than transplant-eligibility and the R-ISS.